Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results: Strong Growth, Strategic Moves, and Ambitious 2026 Outlook

Germantown, Md. – March 2, 2026: Senseonics Holdings, Inc. (NASDAQ: SENS), a leading medical technology company specializing in long-term, implantable continuous glucose monitoring (CGM) systems, has announced its financial results for the fourth quarter and full year ended December 31, 2025. The company also provided a comprehensive business update and financial outlook for 2026, highlighting major achievements and future growth drivers.

Key Financial Highlights

• Fourth Quarter 2025 Revenue: \$14.3 million, up 72% year-over-year from \$8.3 million in Q4 2024.
• Full Year 2025 Revenue: \$35.3 million, up 57% from \$22.5 million in 2024.
• U.S. Revenue: \$12.1 million in Q4 2025 (from \$6.2 million in Q4 2024); \$27.9 million in 2025 (from \$15.3 million in 2024).
• Gross Profit: \$7.7 million in Q4 2025 (from \$4.0 million in Q4 2024); \$15.8 million for 2025 (from \$0.5 million in 2024).
• Net Loss: \$20.8 million (\$0.46/share) in Q4 2025 vs. \$15.5 million (\$0.46/share) in Q4 2024; \$69.1 million (\$1.66/share) for 2025 vs. \$78.6 million (\$2.50/share) in 2024.
• Cash, Cash Equivalents & Investments: \$94.3 million as of December 31, 2025.
• Outstanding Indebtedness: \$35.3 million as of year-end 2025.

Operational and Strategic Highlights

• New Patient Growth: U.S. new patient growth reached 103% in 2025 vs. 2024, largely attributed to effective direct-to-consumer (DTC) marketing.
• HCP Channel Expansion: Over 80% growth in active healthcare provider (HCP) prescribers from 2024 to 2025.
• Eon Care Inserter Network: Expanded to 60 providers, performing 24% of all U.S. insertions in 2025.
• Regulatory & Product Milestones:
  • Received CE Mark approval for Eversense 365 in the European Union, paving the way for European commercialization.
  • Secured FDA Investigational Device Exemption (IDE) approval to commence a pivotal trial for the self-powered battery-enabled Gemini sensor. The first patients have been enrolled, with trial completion expected in H2 2026.
• Product Launches & Partnerships:
  • Launched the first Eversense 365 Automated Insulin Delivery (AID) system integration with twiist™ in the U.S.
  • Announced the transition of Eversense commercialization and distribution from Ascensia Diabetes Care back to Senseonics, effective January 1, 2026.

Management Commentary & Strategic Outlook

Tim Goodnow, PhD, President and CEO, emphasized Senseonics’ strategic actions in 2025, notably bringing commercial operations in-house and ramping up DTC marketing. These moves, alongside product innovations, are viewed as foundational steps for long-term growth and maximizing the potential of their year-long CGM system. The company expects continued momentum into 2026, with plans to:

• Expand Eversense 365 compatibility with more AID systems
• Launch Eversense 365 in Europe following CE Mark approval
• Complete the pivotal Gemini sensor trial, a key pipeline milestone
• Drive improved gross margins through operational efficiencies and higher product sales

2026 Financial Outlook

• Projected 2026 Global Net Revenue: \$58–\$62 million, representing 65–76% year-over-year growth as Senseonics completes the transition from Ascensia and scales its in-house sales and marketing.
• Expected Gross Margins: Approximately 50% for the full year.

This outlook factors in the full commercial transition, the Eversense 365 roll-out outside the U.S., ongoing DTC marketing investments, and utilization of patient assistance programs.

Detailed Financials

• Operating Expenses:
  • Research & Development (R&D): \$31.6 million for 2025, down from \$41.1 million in 2024, driven by completion of key clinical trials and reduced headcount.
  • Selling, General & Admin (SG&A): \$52.5 million for 2025, up from \$34.2 million, reflecting higher sales and marketing costs (mainly DTC campaigns and increased sales commissions) and expenses related to taking over commercialization.
• Balance Sheet:
  • Total Assets: \$126.3 million at year-end 2025 (up from \$100.4 million in 2024).
  • Total Liabilities: \$65.2 million at year-end 2025 (down from \$79.3 million in 2024).
  • Stockholders’ Equity: Improved to \$61.0 million at year-end 2025 from a deficit of \$(16.6) million in 2024, driven by capital raises and improved operating results.

Potential Price-Sensitive Information for Shareholders

• Significant Revenue Growth: Both in the U.S. and globally, Senseonics demonstrated rapid top-line growth, which could positively impact investor sentiment.
• CE Mark Approval & European Rollout: Regulatory clearance in the EU for Eversense 365 opens new market opportunities and revenue streams.
• Direct Control of Commercialization: Taking back U.S. commercialization from Ascensia allows greater control over branding, margins, and customer engagement, but also introduces execution risk.
• Ramping DTC Marketing and HCP Channels: Accelerated investments in DTC and HCP channels are expected to drive further adoption, albeit at the cost of higher SG&A in the near term.
• Pipeline Progress: The Gemini sensor pivotal trial commencement and expected completion in H2 2026 signal ongoing innovation, possibly supporting long-term valuation.
• Improved Margins: Favorable gross margin trends, driven by new product economics and reduced manufacturing costs, could have a positive impact on profitability trajectory.
• 2026 Guidance: Aggressive revenue and margin targets for 2026 could set high investor expectations and drive share price volatility depending on execution and market conditions.
• Net Loss Narrowed: Although still operating at a loss, the company narrowed its annual net loss by \$9.5 million year-over-year, reflecting improving operating leverage.

Risks and Forward-Looking Statements

• Execution risk in the transition of commercialization from Ascensia to in-house teams.
• Regulatory, reimbursement, and competitive risks in the U.S. and EU markets.
• Dependence on successful completion and commercialization of new pipeline products, such as the Gemini sensor.
• Potential macroeconomic and political headwinds, including tariffs and supply chain uncertainties.

Conclusion

Senseonics delivered a transformational year in 2025, with robust revenue growth, expanded market access, and ambitious plans for 2026. The CE Mark approval, strategic commercial shifts, product launches, and rapidly growing U.S. patient base are all key factors that could influence the company’s future share price. Investors should closely watch Senseonics’ execution on its 2026 guidance, the European rollout, and progress on pipeline products, as both upside potential and risks remain elevated.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with a licensed financial advisor before making any investment decisions regarding Senseonics Holdings, Inc. Forward-looking statements are subject to risks and uncertainties, and actual results may differ materially from projections.

View Senseonics Holdings, Inc. Historical chart here